Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England
Name:
eJHaem - 2024 - Fox - Real‐world ...
Size:
437.4Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Fox, C. P.Townsend, W.
Gribben, J. G.
Menne, T.
Kalakonda, N.
Williams, P.
Toron, F.
Tyas, E.
Cooper, M.
Rickards, J.
Radford, John
Affiliation
Manchester Academic Health Science Centre The Christie NHS Foundation Trust and University of Manchester Manchester UK.Issue Date
2024
Metadata
Show full item recordAbstract
Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.Citation
Fox CP, Townsend W, Gribben JG, Menne T, Kalakonda N, Williams P, et al. Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England. EJHaem. 2024 Oct;5(5):992-7. PubMed PMID: 39415902. Pubmed Central PMCID: PMC11474359. Epub 2024/10/17. eng.Journal
EJHaemDOI
10.1002/jha2.970PubMed ID
39415902Additional Links
https://dx.doi.org/10.1002/jha2.970Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1002/jha2.970
Scopus Count
Collections
Related articles
- Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis.
- Authors: Puckrin R, Stewart DA, Shafey M
- Issue date: 2022 Apr
- Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy.
- Authors: Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB
- Issue date: 2024 Oct
- Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
- Authors: Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F
- Issue date: 2023 Oct
- Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
- Authors: Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB
- Issue date: 2022 Sep
- Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
- Authors: Saeedian M, Badaracco J, Botros A, Gitlin M, Keating SJ
- Issue date: 2023 Nov